301103 Liaoning He Eye Hospital Group
- 22.41
- +0.35+1.59%
Liaoning He Eye Hospital Group News
Technology advocates goodness. He Eye Care is joining forces from all sides to protect the eye health of the elderly and children.
Recently, Heshi Ophthalmology has joined forces from various parties to launch eye care public welfare activities in many parts of the country, guarding the eye health of the elderly and children, popularizing scientific eye care knowledge to the people, enhancing awareness of eye care, and working together to promote social harmony and healthy development. Love accompanying blind school children to experience the wonderful scientific journey. On May 28th, the 10th "Love Light, June 1st, We Are Together" event kicked off at the Liaoning Science and Technology Museum. The children of Shenyang Blind School, accompanied by caring people, came to the Liaoning Science and Technology Museum to feel the charm of technology up close. This event was organized by Liaoning Science and Technology Museum, Heshi Ophthalmology, Shenyang Blind School, and Love Light Blindness Prevention.
Ho's Ophthalmology (301103.SZ) has repurchased a total of 1.71% of its shares at a cost of 668.71 million yuan
Zhitong Finance App News, Ho's Ophthalmology (301103.SZ) announced that as of May 31, 2024, the company had repurchased a total of 2.696,700 shares of the company's shares through a dedicated securities account, accounting for 1.71% of the company's current total share capital. The highest transaction price was 31.36 yuan/share, the minimum transaction price was 19.98 yuan/share, and the total transaction amount was 668.71 million yuan (excluding transaction fees).
Ho's Ophthalmology released its first ESG report highlighting the original intention of achieving excellence
Recently, Ho's Ophthalmology (301103.SZ) revealed the first Environmental, Social and Corporate Governance (ESG) report, which showcased in detail Ho's ophthalmology's efforts and achievements in various areas such as technological innovation, social responsibility, talent development, environmental protection initiatives, and corporate governance, highlighting the firm determination of the company to keep its original intention and build a “digital bright city” through innovation. Technology for good creates a human-centered eye health system Since its establishment, Ho's Ophthalmology has always adhered to scientific and technological innovation as the lead, committed to the “Guangming City” plan built by the founder, adhering to the core values of “contributing to society, people's trust, leading innovation, and creating happiness together” and
The Recent 9.7% Gain Must Have Brightened CEO Wei He's Week, Liaoning He Eye Hospital Group Co., LTD.'s (SZSE:301103) Most Bullish Insider
Key Insights Insiders appear to have a vested interest in Liaoning He Eye Hospital Group's growth, as seen by their sizeable ownership 51% of the business is held by the top 5 shareholders Instit
Ho's Ophthalmology (301103.SZ) has repurchased a total of 1.32% of its shares at a cost of RMB 51,514,200
Ho's Ophthalmology (301103.SZ) announced that as of April 30, 2024, the company is using centralized bidding transactions...
Ho's Ophthalmology (301103.SZ) has spent 407.109 million yuan to buy back 1.04% of the shares
Zhitong Finance App News, Ho's Ophthalmology (301103.SZ) issued an announcement. As of April 22, 2024, the company had repurchased a total of 1,647,800 shares of the company's shares through a dedicated securities account, accounting for 1.04% of the company's current total share capital. The highest transaction price was 31.36 yuan/share, the minimum transaction price was 19.98 yuan/share, and the total transaction amount was 407.109 million yuan (excluding transaction fees). This repurchase complies with the requirements of the company's share repurchase plan and related laws and regulations.
Liaoning He Eye Hospital Group Co., LTD.'s (SZSE:301103) Stock Going Strong But Fundamentals Look Weak: What Implications Could This Have On The Stock?
Most readers would already be aware that Liaoning He Eye Hospital Group's (SZSE:301103) stock increased significantly by 16% over the past month. However, in this article, we decided to focus on its
Ho's Ophthalmology (301103.SZ): Accumulated cost of RMB 1.056,500 to repurchase 0.23% of shares
Gelonghui, Feb. 2 | Ho's Ophthalmology (301103.SZ) announced that as of January 31, 2024, the company had repurchased 368,120 shares of the company's shares through a dedicated securities account, accounting for 0.23% of the company's current total share capital. The highest transaction price was 31.36 yuan/share, the minimum transaction price was 23.97 yuan/share, and the total transaction amount was 10,056,503.74 yuan.
Liaoning He Eye Hospital Group (SZSE:301103) Could Be Struggling To Allocate Capital
If you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an eye out for. Firstly, we'd want to identify a growing return on capital employ
Ho's Ophthalmology (301103.SZ): First repurchase of 95,900 shares
Glonghui on December 8 | Ho's Ophthalmology (301103.SZ) announced that on December 7, 2023, for the first time, the company repurchased the company's shares through a centralized bidding transaction through a special securities repurchase account. The number of shares repurchased this time was 95,900 shares, accounting for 0.06% of the company's total share capital. The highest transaction price was 31.36 yuan/share, the lowest transaction price was 30.93 yuan/share, and the transaction amount was 2,986,101 yuan.
Ho's Ophthalmology (301103.SZ) plans to jointly invest with professional investment institutions to establish an eye industry fund
Ho's Ophthalmology (301103.SZ) issued an announcement in order to make full use of a wide range of investment institutions in the field of mergers and acquisitions of professional investment institutions...
Ho's Eye Clinic (301103.SZ) granted 6.1 million restricted shares to 471 incentive recipients
Ho's Ophthalmology (301103.SZ) issued an announcement, and the company reviewed and approved the “Adjustment of Restricted Stocks in 2023...
Ho's Ophthalmology (301103.SZ): Plans to spend 68 million yuan to 120 million yuan to buy back the company's shares
Glonghui November 21丨Ho's Eye Clinic (301103.SZ) announced that the company plans to use its own funds to repurchase some of the company's public shares through centralized bidding transactions to implement employee stock ownership plans or equity incentives. The total capital of this repurchase is not less than 67.5 million yuan and no more than 120 million yuan (all inclusive). The specific total amount of repurchase capital is based on the total amount of capital actually used. The repurchase price range is not more than 50.00 yuan/share (including principal amount). Based on the total repurchase capital limit of RMB 67.5 million and the maximum repurchase price of RMB 50.00 per share, it is estimated that shares will be repurchased
Meixin Fund, the major shareholder of Ho's Ophthalmology (301103.SZ) and its co-actors, completed a 3.9% reduction in shares
Ho's Ophthalmology (301103.SZ) announced that the company holds more than 5% of its shareholders, Beijing Xinzhong-Li Meixin Equity Investment Center...
Ho's Ophthalmology (301103.SZ) released the first three quarter results, net profit of 994.105 million yuan, an increase of 51.23%
Ho's Ophthalmology (301103.SZ) released its report for the third quarter of 2023, achieving revenue of 9.4 in the first three quarters...
CEO Wei He, Liaoning He Eye Hospital Group Co., LTD.'s (SZSE:301103) Largest Shareholder Sees Value of Holdings Go Down 6.8% After Recent Drop
Key Insights Liaoning He Eye Hospital Group's significant insider ownership suggests inherent interests in company's expansion The top 5 shareholders own 51% of the company Using data from company
Ho's Ophthalmology (301103.SZ): The target for establishing new optometry centers this year is expected to be around 30
Glonghui, Oct. 19, 丨 Ho's Ophthalmology (301103.SZ) said at an investor relations event on October 19 that the company expects to set up around 30 new optometry centers this year. Currently, the work to establish new optometry centers is being actively promoted. At that time, it will evaluate the new store business situation in 2023 and formulate a new design plan for 2024.
Ho's Ophthalmology (301103.SZ): The market penetration rate of traditional medical treatment programs is not high. With the improvement of medical standards, there is still a lot of market space in the future
Glonghui, Oct. 19丨Ho's Ophthalmology (301103.SZ) said at an investor relations event on October 19 that the market penetration rate of traditional medical treatment programs is not high. As medical standards improve, there is still plenty of market space in the future, and there will continue to be growth in the long run. Consumer healthcare has always been the company's traditional advantage. Combined with continuous investment in digitalization, it is more conducive to the company's expansion in the field of consumer healthcare. The company will continue to cultivate in the field of consumer healthcare.
Ho's Ophthalmology (301103.SZ) plans to grant 7.1 million restricted shares at a grant price of 20 yuan/share
Ho's Ophthalmology (301103.SZ) disclosed the 2023 restricted stock incentive plan (draft), and the company plans to stimulate...
Net profit surged by 87.38%! A Perspective on the Core Values and Growth Context of Ho's Ophthalmology (301103.SZ)
Revenue was 621 million yuan, up 32.66% year on year; net profit of GuiMu was 78.3479 million yuan, a year-on-year increase of 87.38%
Analysis
Price Target
No Data
